Intermittent Hypoxic-Hyperoxic Treatment (IHHT)

Exploring oxygen adaptation through individually assessed care.

At Pathways, decisions about complementary treatment are guided by your individual needs and the available clinical evidence. Intermittent hypoxic-hyperoxic treatment (IHHT) uses carefully controlled changes in the oxygen you breathe to explore the body’s adaptive responses. It is an emerging approach, rather than a proven way to restore cellular health, and requires medical assessment and appropriate supervision.

Feeling better is closer than you think

Understanding IHHT

What treatment involves, its potential applications and the developing evidence.

What is IHHT?

Intermittent hypoxic-hyperoxic treatment involves alternating periods of breathing air with lower oxygen content (hypoxia) and higher oxygen content (hyperoxia) through a mask connected to specialised equipment. Sessions are usually undertaken while sitting or reclining. Changing the oxygen mixture is intended to stimulate physiological adaptation, drawing on principles associated with exposure to altitude; it does not reproduce every effect of mountain training.

Session length varies by protocol and may be around an hour, including preparation and monitoring. Oxygen saturation and heart rate are monitored, with the exposure adjusted to individual tolerance. Although non-invasive, IHHT is not automatically suitable or risk-free. A clinician should assess relevant medical conditions, particularly heart and lung health, before treatment is considered. Symptoms or poor tolerance require prompt attention and adjustment or stopping.

What is IHHT helpful for?

Research has explored IHHT in selected rehabilitation settings, including older adults with cardiovascular, metabolic or cognitive difficulties. Some small studies suggest improvements in exercise tolerance, aspects of cognition and certain cardiometabolic measures. Researchers are also investigating oxygen-sensitive cellular pathways and how controlled exposure might influence adaptation. These findings do not establish that IHHT regenerates cells, reliably boosts energy or reverses disease.

Claims about better sleep, stress resistance, stamina and quality of life need to be considered separately, because evidence differs across outcomes and patient groups. IHHT is not an established treatment for depression, burnout, insomnia or myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), nor a proven way to enhance immunity or treat respiratory disease. Persistent fatigue needs clinical assessment; any proposed use should complement appropriate care rather than replace it.

Is IHHT evidence-based?

IHHT has a developing research base, with encouraging findings alongside important uncertainties. Controlled trials have reported benefits in some physical and cognitive outcomes, while others have found no additional improvement in mobility or perceived health. Studies are often small, use different protocols and combine IHHT with rehabilitation or exercise, making it difficult to establish its independent effects, optimal use and longer-term safety.

The 2019 Nobel Prize in Physiology or Medicine recognised William G. Kaelin Jr., Sir Peter J. Ratcliffe and Gregg L. Semenza for discoveries about how cells sense and adapt to oxygen availability. It was not awarded for IHHT or proof of rejuvenation. At Pathways, any consideration of IHHT should include a discussion of these evidence limits, your medical suitability and measurable goals within your wider treatment plan.

Read our recent blog posts

Specialized support for specific challenges.

How to know when it’s a problem

Why journaling is essential for anxiety relief

5 ways to communicate better with your partner